Watch: RNL23 Vasculitis Faculty Panel Q&A RheumNow Live 2023: Robert Spiera, MD, Hospital for Special Surgery Anisha Dua, MD, MPH, Northwestern University, Feinberg School of Medicine Carol Langford, MD, MHS, FACP https://t.co/4ddqt2tAQ8 https://t.co/KIPp3rePpp

SURPASS: SEC vs ADA for axSpA Outcome: %pts with no radiographic progression Not benefit- Secukinumab not better than adalimumab Though negative study, in all groups the progression was very low (<1 mSASS) - both interventions did well! #RNL2023 https://t.co/xlw4nzrwpm https://t.co/dhhLMFQnhI

Watch: GPA Treatment Choices https://t.co/MU6gZrgYDr https://t.co/lT1jI9jGGS

Colchicine does not work in Hand OA. Danish trial of 100 HOA pts (age 71 yrs) given placebo or COL 0.5 mg bid x 12wk. Finger pain improved –13·9 mm w/ colchicine vs –13·5 mm w/ PBO (NS). More adverse events w/ Colchicine (72% vs 44%) https://t.co/rfANCLcZii https://t.co/OFuMGZSvhm

Risk factors for radiographic progression: Men ♂️ Smoking 🚬 Active inflammation🔥 Blue collar workers 💪 HLA-B27+ 💉 Pre-existing syndesmophyte 🩻 Atul Deodhar at #RNL2023 @RheumNow https://t.co/FcwrDtOG6I https://t.co/AvRpPrg1UK

BIOBADASER registry of 3,366 RA/AS/PsA pts on 1,2 bDMARDs saw Remission-related Biologic D/C by 80 pts (2.4%). D/C Factors: short Dz duration (OR: 0.95), no csDMARDs (OR:0.56), shorter use prior bDMARD. Less D/C w/ smoking & ACPA+ https://t.co/iUdU9iI4AZ https://t.co/TknRW6pnJR

INBUILD study was an all cause ILD nintedanib RCT (n=663). Subanalysis of 89 RA-ILD pts showed FVC decline (@ 52 wks) was −82.6 mL/yr on NIN vs −199.3 mL/yr on PBO (p=.037). NIN diarrhea in 62%; & AE discontinuation in 24% https://t.co/nWuGx6wjB2 https://t.co/LVwy1Z5TL3

Dr. Atul Deodhar on AxSpA - 5-40% of nr-axSpA progress to r-axSpA over 2-10 years - is non-radiographic axSpA a misnomer? @RheumNow #RNL2023 https://t.co/HaavCnplO0 https://t.co/3jQaxVfFBH

Dr. Deodhar reminds us of his "3,4,5 rule" for diagnosing AS. *Erosions in 3 or more SIJ quadrants *BME in 4 or more SIJ quadrants *Fat lesions in 5 of more SIJ quadrants #RNL2023 @RheumNow https://t.co/6iAXKfZvEY https://t.co/kxqbiXVd2w

#RNL2023 @RheumNow Atul Deodhar: Prevalence of AS is increasing! Is it truly more? Or likely better recognized and diagnosed, as well as increased recognition of nr-AxSpa https://t.co/HnzRrKko75 https://t.co/CBbvFIbRoi

Allergic Drug-Induced Arthritis Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/iRqfkFu52z. This week we delve into some odd associations, repeat drug warnings and the consequences of antirheumatic therapies. https://t.co/lRBaXMAgz6 https://t.co/37gIHniIEi